The use of biosimilar drugs – which mimic existing biologic drugs – could reduce U.S. drug costs by more than $100 billion over the next five years. However, there are still challenges in getting these lower-cost medications into the hands of patients. Savitha Vivian, Senior Vice President, Clinical and Formulary Services at Optum Rx, discusses the pipeline of biosimilar drugs – including a highly-anticipated 2023 launch – and how broader use of biosimilars could improve prescription drug affordability for patients.